OncoHost Proteomics Lab Earns CAP Accreditation

Original source here.

OncoHost Proteomics Lab Earns CAP Accreditation

Dec 3, 2024    

Summary: OncoHost’s CLIA-certified proteomics laboratory received CAP accreditation, emphasizing its commitment to delivering precision-focused diagnostics for improved cancer care.

Takeaways:

1. Commitment to Excellence: CAP accreditation highlights OncoHost’s adherence to rigorous quality and safety standards in its Cary laboratory, ensuring reliable diagnostic results for precision oncology.
2. Innovative PROphet Platform: OncoHost’s proprietary PROphet tool analyzes over 7,000 proteins from a single blood sample to guide personalized cancer treatment by predicting therapeutic benefit.
3. Advancing Precision Medicine: This milestone reinforces OncoHost’s mission to empower healthcare providers with cutting-edge, data-driven tools that optimize patient outcomes and redefine standards in cancer care.

OncoHost, a technology company focused on precision medicine for improved patient outcomes, announced that its CLIA-certified, high-throughput proteomics laboratory in Cary, North Carolina, received accreditation from the College of American Pathologists (CAP).

Getting CAP Accreditation

This accreditation underscores OncoHost’s commitment to the highest standards of quality and safety in laboratory practices. Its Cary facility is among a select group of specialized proteomics labs focused on human host response analysis and one of the only industrial-level operations dedicated to this purpose.

“We are honored to achieve CAP accreditation, a testament to our commitment to delivering the highest quality diagnostics,” said Amir Gelman, PhD, Director of Laboratory Operations & Assay Development at OncoHost. “This recognition reflects our dedication to precision and stringent compliance, ensuring healthcare providers and patients can trust the results guiding critical decisions in their cancer care.”

OncoHost’s Proteomics Platform

Central to OncoHost’s approach is its proprietary PROphet platform, a plasma-based proteomic pattern recognition tool that combines systems biology, bioinformatics, and artificial intelligence to support clinical decision-making.

Requiring only a single pre-treatment blood sample, PROphet analyzes patterns across approximately 7,000 proteins to generate a PROphet score—a clinically validated metric that reflects a patient’s likelihood of clinical benefit. This insight allows for effective and personalized treatment decisions, supporting patient-specific plans based on the unique biology of each individual. By predicting the likelihood of benefit from therapies such as immunotherapy alone or in combination with chemotherapy, PROphet enables physicians to make informed choices, reduce unnecessary treatments, and optimize patient survival.

‍